Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for Prevention of PICC-Related Thrombosis in Cancer Patients
ChiCTR-IIR-17011109Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Symptomatic PICC-related upper extremity venous thrombosis. Planned start May 2017; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR-IIR-17011109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17011109.